查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1929673

轮状病毒疫苗市场按疫苗类型、剂型、通路和最终用户划分，全球预测（2026-2032年）

Rotavirus Vaccine Market by Vaccine Type, Presentation, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，轮状病毒疫苗市场价值将达到 41.2 亿美元，到 2026 年将成长至 44.4 亿美元，到 2032 年将达到 65.6 亿美元，复合年增长率为 6.85%。

关键市场统计数据
基准年 2025 41.2亿美元
预计年份：2026年 44.4亿美元
预测年份 2032 65.6亿美元
复合年增长率 (%) 6.85%

策略性实施方案整合了临床进展、供应挑战、监管趋势和相关人员的优先事项，为轮状病毒决策提供直接且清晰的指导。

轮状病毒疫苗目前的市场地位使其在儿童感染疾病预防和公共卫生规划中发挥了核心作用。近期临床进展、计画推广以及不断发展的低温运输物流，使这种疫苗从一种小众干预措施跃升为高所得国家和资源匮乏地区儿童免疫策略的关键组成部分。包括生产商、支付方、公共卫生机构和临床医生在内的相关人员，需要对现有产品的临床概况、获批的监管途径以及影响核准分销和使用的操作注意事项有一个简明扼要的了解。

分析将重塑全球轮状病毒疫苗研发、交付和分发的变革性临床、生产、供应链和专案变化。

在临床创新、生产多样化和专案调整的推动下，轮状病毒疫苗领域正经历变革性的变化。新型疫苗的推出以及针对更广泛温度稳定性和更便捷接种方式的改良配方，正在减少物流摩擦，使卫生署能够考虑在传统接种点之外更广泛地部署疫苗。同时，疫苗配方和接种方案的逐步改进也促使政策制定者加强对低温运输的投入，并重新评估第一线医护人员的培训需求。

对2025年关税政策和贸易措施变化对轮状病毒供应链韧性、采购选择和生产策略的影响全面评估

关税政策和贸易措施的变化可能会对疫苗供应链、生产成本和筹资策略产生连锁反应，2025年关税调整的累积影响需要仔细评估。提高某些原材料、包装材料或成品的进口关税可能会增加采购者的到岸成本，这可能导致采购转向区域製造商和垂直整合的供应商，这些供应商将更多价值链内部化。相反，降低关税或对基本医疗用品进行有针对性的豁免，并结合更有效率的海关程序，则有助于提高疫苗的可负担性和可及性。

透过对疫苗类型、通路、最终用户和剂型进行关键細項分析，揭示了专案优化的营运槓桿和商业性路径。

细分市场分析突显了商业性和专案方面的机会，以及为满足不同相关人员的需求而需要进行的战术性调整。基于疫苗类型的临床和监管过程表明，活病毒疫苗更适合大规模免疫接种计划，而灭活疫苗作为一种替代方案正在兴起，其在稳定性和特定人群适用性方面具有潜在优势。这种差异决定了临床训练需求、给药通讯协定和上市后监测重点的不同。

整合美洲、欧洲、中东和非洲以及亚太地区的临床实施现况、供应链实际情况和政策措施，以指南部署策略。

区域背景影响着计画优先事项、医疗服务提供者的参与以及实施模式。了解这些差异对于制定有效策略至关重要。在美洲，长期实施的常规免疫规划和完善的低温运输基础设施使得口服轮状病毒疫苗得以广泛纳入国家免疫计划，私人医疗机构和药房在都市区补充了公共供应。该地区也凸显了健全的监测系统对于检测流行株的变化以及长期监测疫苗有效性的重要性。

检验跨国公司与本土开发商之间影响轮状病毒疫苗供应和性能的竞争动态、合作模式和技术差异。

竞争格局呈现出多元化的格局，既有跨国疫苗研发企业，也有区域性生产商，还有追求诸如热稳定性、便捷给药方式和差异化配方等利基优势的新兴企业。成熟的全球研发企业已建立起完善的监管先例和广泛的上市后监测网络，从而能够将其产品广泛纳入国家免疫规划。区域性生产商则通常在​​成本、供应稳定性和对当地法规的熟悉程度上展开竞争，并经常透过技术转移和合作生产协议与政府建立伙伴关係，以扩大产能并缩短前置作业时间。

为製造商、采购负责人和专案经理提供具体建议，以加强供应安全、优化服务提供，并加快在各种环境下的免疫接种覆盖率。

产业领导者应采取多管齐下的方法，在保障供应安全与临床和营运卓越性之间取得平衡。首先，优先选择能够减少低温运输压力、缩短现场配製时间的配方，从而提高繁忙诊所的效率，并减少操作失误的发生。其次，建立多元化的供应商网络和区域性生产伙伴关係，以降低单一来源风险，并快速应对贸易和关税政策的变化。

我们采用严谨的多学科研究方法，结合关键相关人员对话、监管审查、产品评估和营运案例研究，以确保获得切实可行的、基于证据的见解。

该分析采用了一种结构化的、以证据主导的调查方法，结合了关键相关人员访谈、监管审查、产品文件评估和营运案例研究。与临床医生、采购专业人员、物流经理和技术顾问的讨论为了解不同供应环境下的实际限制和决策标准提供了关键资讯。研究人员查阅了监管和临床文献，以协调核准途径、标籤差异和安全监测要求，并基于产品技术简报对剂型和操作特性进行了比较分析。

简洁扼要的结论强调了临床可靠性、操作适应性和政策一致性如何共同作用，从而在各种环境下维持轮状病毒疫苗的有效性。

轮状病毒疫苗市场的特点是技术创新、供应链策略不断演变以及专案适应性日益重要。活病毒疫苗疫苗仍然是大多数免疫规划的基础，而製剂和剂型的创新正在扩大冷链能力受限地区的疫苗覆盖范围。关税和贸易政策趋势会影响采购选择，应透过采购多元化和区域合作来应对，以保障供应的连续性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 轮状病毒疫苗市场（依疫苗类型划分）

  • 失活
  • 口服减毒活疫苗

9. 轮状病毒疫苗市场（依剂型划分）

  • 液体
    • 多用途管瓶
    • 预填充式注射器
  • 冷冻干燥製剂
    • 多用途管瓶
    • 免洗管瓶

10. 轮状病毒疫苗市场依通路划分

  • 诊所
  • 医院药房
  • 网路药房
  • 零售药房

第十一章 轮状病毒疫苗市场（以最终用户划分）

  • 诊所
    • 一般诊所
    • 小儿科诊所
  • 社区医疗中心
    • 医院设施
    • 独立的
  • 医院
    • 私立医院
    • 公立医院

12. 各地区轮状病毒疫苗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 轮状病毒疫苗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国轮状病毒疫苗市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国轮状病毒疫苗市场

16. 中国轮状病毒疫苗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bharat Biotech International Limited
  • Bio Farma
  • Biological E. Limited
  • Cadila Healthcare Limited
  • GlaxoSmithKline plc
  • Hilleman Laboratories
  • Indian Immunologicals Limited
  • Lanzhou Institute of Biological Products Co., Ltd.
  • Merck & Co., Inc.
  • Novavax, Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Shantha Biotechnics
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Valneva SE
Product Code: MRR-0A3806951885

The Rotavirus Vaccine Market was valued at USD 4.12 billion in 2025 and is projected to grow to USD 4.44 billion in 2026, with a CAGR of 6.85%, reaching USD 6.56 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.12 billion
Estimated Year [2026] USD 4.44 billion
Forecast Year [2032] USD 6.56 billion
CAGR (%) 6.85%

A strategic introduction that synthesizes clinical advances, delivery challenges, regulatory dynamics, and stakeholder priorities to position rotavirus decision making for immediate clarity

The rotavirus vaccine landscape now occupies a central role in pediatric infectious disease prevention and public health planning. Recent clinical progress, programmatic rollouts, and evolving cold chain logistics have elevated the vaccine from a niche intervention to a critical component of childhood immunization strategies in both high-income and resource-constrained settings. Stakeholders across manufacturers, payers, public health authorities, and clinicians require a concise orientation to the clinical profile of existing products, the regulatory pathways that enabled their approval, and the operational considerations that govern their distribution and administration.

This introduction frames the essential dynamics that influence vaccine selection, procurement decisions, and program implementation. It synthesizes clinical efficacy and safety evidence, highlights delivery-route distinctions, and underscores the interface between supply-side innovations and service delivery models. By establishing this context, readers can better evaluate subsequent sections that delve into strategic shifts, trade policy impacts, segmentation nuances, regional patterns, and actionable recommendations tailored to accelerating protective coverage while maintaining program resilience.

An analysis of transformative clinical, manufacturing, supply chain, and programmatic shifts reshaping how rotavirus vaccines are developed, delivered, and adopted globally

The rotavirus vaccine arena has experienced transformative shifts driven by clinical innovation, manufacturing diversification, and programmatic adaptation. New entrants and reformulations designed for broader thermostability and simpler administration have reduced logistical friction, enabling ministries of health to consider wider deployment beyond traditional immunization sites. In parallel, incremental improvements in vaccine presentation and dosing schedules have encouraged policymakers to re-evaluate cold chain investments and training requirements for frontline providers.

Concurrently, global health partnerships and bilateral procurement arrangements have influenced supply chain architecture, prompting manufacturers to expand regional production capabilities and engage in technology transfer initiatives. These shifts have also accelerated interest in alternative delivery channels, including increased use of outpatient clinics and targeted community programs. Finally, enhanced real-world safety surveillance and post-introduction monitoring have strengthened confidence among clinicians and caregivers, thereby improving uptake in settings where vaccine hesitancy had been a barrier. Together, these changes create a more resilient, flexible ecosystem that supports both routine immunization and targeted catch-up strategies.

A comprehensive assessment of how changes in tariff policy and trade measures in 2025 influence rotavirus supply chain resilience, procurement choices, and manufacturing strategies

Changes in tariff policy and trade measures can create ripple effects across vaccine supply chains, manufacturing costs, and procurement strategies, and the cumulative impact of tariff adjustments in 2025 warrants careful examination. Elevated import tariffs on certain raw materials, packaging, or finished doses can increase landed costs for procurers, which in turn may shift procurement preferences toward regional manufacturers or vertically integrated suppliers that internalize more of the value chain. Conversely, tariff relief or targeted exemptions for essential medical goods can improve affordability and expand access when coupled with streamlined customs processes.

Beyond direct cost implications, tariffs influence inventory planning, lead times, and supplier diversification. Procurement teams may lengthen safety stock or seek multiple qualified suppliers to mitigate the risk of sudden tariff changes, and policy uncertainty can push national programs to prioritize domestic or regional manufacturing capacity as a long-term resilience strategy. Importantly, the impact of tariffs interacts with regulatory harmonization, trade agreements, and logistics capacity; thus, a holistic response that combines trade advocacy, strategic sourcing, and supply chain redesign typically yields the most durable mitigation against tariff-driven disruptions.

Key segmentation insights across vaccine type, distribution channels, end users, and presentation formats that reveal operational levers and commercial pathways for program optimization

Segmentation analysis clarifies where commercial and programmatic opportunities exist and what tactical adjustments are required to meet diverse stakeholder needs. Based on vaccine type, the clinical and regulatory history favors live attenuated oral products for widespread immunization programs, while inactivated formulations are emerging as alternative approaches with potential advantages in stability and suitability for specific populations. This distinction drives different clinical training needs, administration protocols, and post-marketing surveillance priorities.

Based on distribution channel, clinics traditionally serve as the primary access point for routine immunizations, supported by hospital pharmacies for inpatient settings, with retail and online pharmacies increasingly playing a role in catch-up and private market segments where permitted. Based on end user, the delivery landscape spans general and pediatric clinics, community health centers that may be hospital based or standalone, and hospitals that operate as private or public providers; each end user type exhibits distinct procurement routines, cold chain capacity, and reporting mechanisms. Based on presentation, liquid formats-available as multi-dose vials or prefilled syringes-offer ease of administration and reduced preparation time, whereas lyophilized options-packaged as multi-dose or single-dose vials-provide extended shelf life under constrained cold chain conditions, albeit with added reconstitution requirements. Integrating these segmentation lenses yields a nuanced picture of where innovation, service redesign, and targeted communication can increase coverage and reduce wastage.

A regional synthesis of clinical implementation, supply chain realities, and policy levers across the Americas, Europe Middle East & Africa, and Asia Pacific that informs deployment strategy

Regional context shapes program priorities, supplier engagement, and implementation models, and appreciating these differences is essential for effective strategy development. In the Americas, longstanding routine immunization programs and established cold chain infrastructure enable broad incorporation of oral rotavirus vaccines into national schedules, with private sector providers and pharmacies supplementing public delivery in urban centers. This region also demonstrates the importance of robust surveillance systems that detect shifts in circulating strains and monitor vaccine effectiveness over time.

In Europe, Middle East & Africa, heterogeneous health system maturity yields varied adoption timelines and financing models; high-capacity national programs coexist with low-resource settings where lyophilized presentations and thermostable formulations improve reach. Donor-supported initiatives and regional procurement mechanisms play a significant role in expanding access, while emergent local manufacturing capacity in some countries is beginning to alter supplier dynamics. In Asia-Pacific, diverse market structures include both large public immunization programs and significant private market demand; manufacturers that tailor presentations and packaging to local logistics constraints, and that engage with regional regulatory harmonization efforts, tend to gain traction. Across all regions, alignment between clinical guidance, supply chain investment, and community engagement remains a decisive factor for long-term program success.

An examination of competitive dynamics, collaboration models, and technical differentiators among multinational and regional developers shaping rotavirus vaccine availability and performance

Competitive dynamics reflect a mix of multinational vaccine developers, regional manufacturers, and newer entrants pursuing niche advantages such as thermostability, simplified delivery, or differentiated presentations. Established global developers have built regulatory precedents and extensive post-marketing surveillance networks that support broad inclusion in national schedules. Regional producers often compete on cost, supply security, and local regulatory familiarity, and they frequently collaborate with governments through technology transfer or co-manufacturing agreements to expand capacity and shorten lead times.

Partnerships between public and private participants, as well as investments in formulation science, have catalyzed product variants that address specific logistical constraints. Companies that align development priorities with end-user needs-focusing on cold chain optimization, multi-dose versus single-dose trade-offs, and ease of integration into routine immunization visits-are positioned to capture private-market demand while supporting public-sector programs. Strategic engagement with regulators, procurement agencies, and implementing partners further differentiates organizations that can deliver reliable supply and responsive technical support in diverse operating environments.

Actionable recommendations for manufacturers, procurers, and program leaders to strengthen supply security, optimize service delivery, and accelerate protective coverage across diverse settings

Industry leaders should adopt a multi-pronged approach that balances supply security with clinical and operational excellence. First, prioritize formulation and presentation choices that reduce cold chain burden and minimize preparation time at the point of care, thereby improving throughput in busy clinics and reducing opportunities for handling errors. Second, establish diversified supplier networks and regional manufacturing partnerships to mitigate single-source risk and to respond rapidly to shifts in trade or tariff policy.

Third, invest in post-introduction monitoring, pharmacovigilance, and targeted communication campaigns that build confidence among clinicians and caregivers, particularly in areas with historically lower uptake. Fourth, tailor distribution strategies to the realities of end users-differentiating between general and pediatric clinics, hospital-based and standalone community centers, and private versus public hospitals-to ensure that procurement, training, and reporting systems match operational capacity. Finally, engage proactively with policymakers and trade stakeholders to advocate for tariff treatments and customs processes that preserve affordability and expedite delivery of essential vaccines, while also exploring flexible contracting mechanisms that de-risk supply commitments during periods of policy uncertainty.

A rigorous multi-method research approach combining primary stakeholder engagement, regulatory review, product assessment, and operational case studies to ensure practical, evidence-based findings

This analysis integrates a structured, evidence-driven research methodology combining primary stakeholder interviews, regulatory review, product dossier assessment, and operational case study synthesis. Primary inputs included consultations with clinicians, procurement specialists, logistics managers, and technical advisors to capture real-world constraints and decision criteria across delivery settings. Regulatory and clinical literature were reviewed to reconcile approval pathways, labeling distinctions, and safety monitoring requirements, while product technical briefs informed comparative analysis of presentation and handling attributes.

Operational case studies examined cold chain logistics, clinic workflows, and pharmacist practices to understand distribution channel implications. Trade and policy impacts were evaluated through scenario analysis that considered tariff variability, customs processing, and supplier diversification strategies. Throughout, findings were triangulated across multiple sources to ensure internal consistency and to highlight robust conclusions versus areas requiring further localized investigation. This methodology emphasizes practical relevance and replicability to support client-specific follow-up work and targeted diligence.

A concise conclusion highlighting how clinical credibility, operational adaptability, and policy engagement converge to sustain rotavirus immunization impact across heterogeneous contexts

The rotavirus vaccine environment is characterized by technical innovation, evolving supply chain strategies, and an increased emphasis on programmatic fit. Live attenuated oral vaccines remain the operational backbone of most immunization schedules, while innovations in formulation and presentation are expanding the feasible footprint in settings with constrained cold chain capacity. Tariff and trade policy dynamics can influence procurement choices and should be managed through diversified sourcing and regional collaboration to protect continuity of supply.

Segmentation by vaccine type, distribution channel, end user, and presentation reveals targeted opportunities to reduce wastage, improve administration efficiency, and align product design with point-of-care realities. Regionally tailored approaches that reflect differences in infrastructure, financing, and regulatory pathways will yield the highest returns in coverage and impact. In sum, stakeholders that combine clinical credibility, operational adaptability, and proactive policy engagement will be best positioned to improve child health outcomes through sustained, equitable access to rotavirus vaccination.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Rotavirus Vaccine Market, by Vaccine Type

  • 8.1. Inactivated
  • 8.2. Live Attenuated Oral

9. Rotavirus Vaccine Market, by Presentation

  • 9.1. Liquid
    • 9.1.1. Multi-dose Vial
    • 9.1.2. Prefilled Syringes
  • 9.2. Lyophilized
    • 9.2.1. Multi-dose Vial
    • 9.2.2. Single-dose Vial

10. Rotavirus Vaccine Market, by Distribution Channel

  • 10.1. Clinics
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Rotavirus Vaccine Market, by End User

  • 11.1. Clinics
    • 11.1.1. General Clinics
    • 11.1.2. Pediatric Clinics
  • 11.2. Community Health Centers
    • 11.2.1. Hospital Based
    • 11.2.2. Standalone
  • 11.3. Hospitals
    • 11.3.1. Private Hospitals
    • 11.3.2. Public Hospitals

12. Rotavirus Vaccine Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Rotavirus Vaccine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Rotavirus Vaccine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Rotavirus Vaccine Market

16. China Rotavirus Vaccine Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bharat Biotech International Limited
  • 17.6. Bio Farma
  • 17.7. Biological E. Limited
  • 17.8. Cadila Healthcare Limited
  • 17.9. GlaxoSmithKline plc
  • 17.10. Hilleman Laboratories
  • 17.11. Indian Immunologicals Limited
  • 17.12. Lanzhou Institute of Biological Products Co., Ltd.
  • 17.13. Merck & Co., Inc.
  • 17.14. Novavax, Inc.
  • 17.15. Panacea Biotec Ltd.
  • 17.16. Pfizer Inc.
  • 17.17. Sanofi S.A.
  • 17.18. Serum Institute of India Pvt. Ltd.
  • 17.19. Shantha Biotechnics
  • 17.20. Sinovac Biotech Ltd.
  • 17.21. Takeda Pharmaceutical Company Limited
  • 17.22. Valneva SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ROTAVIRUS VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ROTAVIRUS VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY PRESENTATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ROTAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ROTAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY MULTI-DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY MULTI-DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY MULTI-DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY PREFILLED SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY PREFILLED SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY MULTI-DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY MULTI-DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY MULTI-DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY SINGLE-DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY SINGLE-DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY SINGLE-DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY PEDIATRIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY PEDIATRIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY PEDIATRIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITAL BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITAL BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITAL BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY STANDALONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY STANDALONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY STANDALONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ROTAVIRUS VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ROTAVIRUS VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ROTAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ROTAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ROTAVIRUS VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ROTAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ROTAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ROTAVIRUS VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ROTAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ROTAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ROTAVIRUS VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ROTAVIRUS VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ROTAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ROTAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ROTAVIRUS VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ROTAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ROTAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST ROTAVIRUS VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ROTAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ROTAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ROTAVIRUS VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ROTAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA ROTAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ROTAVIRUS VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ROTAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ROTAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN ROTAVIRUS VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN ROTAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN ROTAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 166. GCC ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GCC ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC ROTAVIRUS VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 169. GCC ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 170. GCC ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED, 2018-2032 (USD MILLION)
  • TABLE 171. GCC ROTAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. GCC ROTAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. GCC ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 174. GCC ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 175. GCC ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION ROTAVIRUS VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION ROTAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION ROTAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS ROTAVIRUS VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS ROTAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS ROTAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 196. G7 ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. G7 ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. G7 ROTAVIRUS VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 199. G7 ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 200. G7 ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED, 2018-2032 (USD MILLION)
  • TABLE 201. G7 ROTAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. G7 ROTAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. G7 ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 204. G7 ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 205. G7 ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 206. NATO ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. NATO ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. NATO ROTAVIRUS VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 209. NATO ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 210. NATO ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED, 2018-2032 (USD MILLION)
  • TABLE 211. NATO ROTAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. NATO ROTAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. NATO ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 214. NATO ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 215. NATO ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES ROTAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES ROTAVIRUS VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES ROTAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES ROTAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA ROTAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA ROTAVIRUS VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA ROTAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA ROTAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA ROTAVIRUS VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA ROTAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)